Europe approves human embryonic stem cell trials for the first time

A biotechnology company was approved by the UK's medicine regulator to conduct human embryonic stem cell trials. This is the first clinical trial of human embryonic stem cells that was ever approved in Europe.

Advanced cell technology company, headquarter is in Massachusetts, the United States, announced on Tuesday that it has been approved by the UK's medicines and healthcare products authority and the genetic therapy advisory committee to conduct clinical trials on adolescent blindness using by human embryonic stem cells.

This is the first europe-wide approval for a clinical trial of human embryonic stem cells, according to Reuters. "This is another important milestone for advanced cell technology and regenerative medicine," said Gary rabin, CEO and chairman of the board of directors of advanced cell technology, in a statement.

Advanced cell technology company was approved in November in the United States to begin a clinical trial using human embryonic stem cells to treat sgert's disease, which is known as hereditary macular degeneration in adolescents, agence france-presse reported. The disease can possibly cause blindness in teenagers.

At present, there are about 80,000 to 100,000 people in the United States and Europe suffering from sgert's disease, which mainly affects teenagers aged 10 to 20 years old. The patients suffer from progressive degeneration of retinal pigment epithelial cells, leading to continuous loss of vision and even blindness.

There is no effective treatment for sigurd's disease. Advanced cell technology company, however, intends to use human embryonic stem cells to grow retinal pigment epithelial cells (rpe), which will then be implanted into the eyes of patients, hoping of using regenerative medicine to treat such diseases.
Related News